Provided by Tiger Fintech (Singapore) Pte. Ltd.

Disc Medicine

47.15
+0.99002.14%
Post-market: 47.150.00000.00%16:05 EDT
Volume:277.06K
Turnover:12.98M
Market Cap:1.63B
PE:-11.90
High:47.38
Open:46.02
Low:45.06
Close:46.16
Loading ...

BRIEF-Disc Medicine Announces Successful End Of Phase 2 Meeting With FDA For Bitopertin In Erythropoietic Protoporphyria

Reuters
·
04 Nov 2024

Disc Medicine Gains FDA Support for Bitopertin Trial

TIPRANKS
·
04 Nov 2024

Disc Medicine announces feedback from FDA End of Phase 2 meeting for bitopertin

TIPRANKS
·
04 Nov 2024

Disc Medicine Inc - to Initiate Apollo Trial by Mid-2025

THOMSON REUTERS
·
04 Nov 2024

Disc Medicine Inc - FDA Agrees With All Proposed Study Parameters for Bitopertin

THOMSON REUTERS
·
04 Nov 2024

Disc Medicine Announces Successful End of Phase 2 Meeting With FDA for Bitopertin in Erythropoietic Protoporphyria (Epp), Including Potential for Accelerated Approval

THOMSON REUTERS
·
04 Nov 2024

Disc Medicine Announces Successful End of Phase 2 Meeting with FDA for Bitopertin in Erythropoietic Protoporphyria (EPP), Including Potential for Accelerated Approval

GlobeNewswire
·
04 Nov 2024

Disc Medicine to Host Conference Call on End of Phase 2 FDA Meeting for Bitopertin in Erythropoietic Protoporphyria (EPP)

GlobeNewswire
·
02 Nov 2024

Press Release: CHAMPION IRON REPORTS ITS FY2025 SECOND QUARTER RESULTS, DECLARES DIVIDEND AND ADVANCES THE DRPF PROJECT AS PLANNED

Dow Jones
·
31 Oct 2024

Disc Medicine Price Target Maintained With a $70.00/Share by HC Wainwright & Co.

Dow Jones
·
28 Oct 2024

Disc Medicine’s Promising Anemia Treatment Drives Buy Rating

TIPRANKS
·
28 Oct 2024

Promising Prospects for Disc Medicine: Innovative Anemia Treatment and Regulatory Milestones Drive Buy Rating

TIPRANKS
·
28 Oct 2024